Acumen. Leadership. Expertise.
The Astute Medical team has extensive industry experience and insights on validation of biomarkers. Our senior leadership team offers expertise in developing, manufacturing and commercialization of products in the health care field.
Paul H. McPherson, PhD | Chief Scientific Officer, Co-Founder
W. Todd Myers | Chief Financial Officer
Karin A. Hughes, PhD | VP of Clinical, Quality and Regulatory Strategy
Ryan N. Roberts | Chief Commercial Officer
Ravi Vijayendran | VP of Product Development
Joe Anderberg | VP of Development Engineering
Mr. Hibberd has more than 20 years’ experience as a leader in business strategy and corporate development. Prior to the founding of Astute Medical in 2007, Mr. Hibberd spent 10 years at Biosite Incorporated, a leading diagnostics company acquired by Inverness Medical Innovations for $1.7 billion. As Senior Vice-President of Corporate Development at Biosite, Mr. Hibberd was co-responsible for the identification and pursuit of strategic business opportunities, including technology acquisitions, partnerships and alliances.
Before joining Biosite, Mr. Hibberd was manager at the Boston Consulting Group (BCG) and was responsible for leading international consultants and client case teams in developing and implementing value-creating strategies for businesses in a variety of industry sectors. Prior to that he held consulting positions at various companies and also was a Development Engineer for Albright & Wilson Americas from 1987 to 1990.
Mr. Hibberd received a Bachelor’s Degree in Chemical Engineering from the University of Toronto, Canada and earned a Master’s in Business Administration from the University of Western Ontario, Canada.
Dr. McPherson has over 25 years’ experience in research and development. He has over 25 issued and pending U.S. patents in areas ranging from immunoassay readers to novel biomarker content in a variety of disease areas.
Prior to co-founding Astute Medical in 2007, Dr. McPherson was vice president of research and development at Biosite Inc., a leading diagnostics company acquired by Inverness Medical Innovations for $1.7 billion. During his 14-year tenure at Biosite, Dr. McPherson led the company’s 85-person research and development team in its hunt for new biomarkers for disease. The team successfully developed and launched eight FDA-cleared products, which included novel diagnostics for congestive heart failure and stroke. He played a key role in the development and commercialization of Biosite’s Triage® Meter Platform and the Triage® family of point-of-care immunoassay products.
Dr. McPherson was a post-graduate research physicist at the University of California, San Diego, where he conducted and published research on the biophysics of photosynthesis.
He earned a doctorate in physics (biophysics) from the University of California, San Diego and a bachelor’s in physics from the University of California, Santa Cruz.
Before joining San Diego-based Astute Medical, Mr. Myers was the chief financial officer at Nexus Biosystems, Inc., a leading innovator and worldwide provider of enabling technologies and automated sample management systems for pharmaceutical, biotechnology, agrichemical and research institutions worldwide.
Mr. Myers also served as chief financial officer at SGX Pharmaceuticals, where he directed the execution of its initial public offering and PIPE financing, facilitated the financial due diligence of a multi-million dollar research collaboration and played a key role in executing the acquisition of the company by Eli Lilly & Company in 2008.
Mr. Myers was also chief financial officer at FeRx Inc. and director of finance at CombiChem Inc. Prior to that, he held positions at Premier Inc. and Ernst & Young LLP.
He is a certified public accountant in the state of California and received his bachelor’s degree in accounting from the University of Illinois.
Ryan Roberts is the chief commercial officer of Astute Medical Inc., a San Diego-based company committed to improving patient outcomes through the identification and validation of novel biomarkers. Mr. Roberts has over 20 years’ experience as a transformational leader with innovative healthcare technology firms spanning the disciplines of radiology, cardiology, orthopedics, pulmonology, orthodontics and oral surgery.
Prior to joining Astute Medical in late 2015, Mr. Roberts led the respiratory capital and software commercial operations for CareFusion, which was acquired by Becton Dickinson for over $12 billion. Previous experience includes delivering market-leading growth through disruptive product and services innovation at OraMetrix, DJO Global, and General Electric Company. At GE Medical Systems, Mr. Roberts’ career matriculated through the Company’s Leadership Development program to roles of increasing responsibility in sales management, commercial operations, marketing, and general management.
Mr. Roberts earned a Bachelor of Science (mechanical engineering) and Bachelor of Arts (design) from The University of Notre Dame. Later he earned a Master’s in Business Administration from The Kellogg School of Management at Northwestern University.
Dr. Ravi Vijayendran is a leader and expert in the development, technology transfer, and manufacturing of rapid test and point-of-care in-vitro diagnostic products. He has 15 years of experience in the research and development of in-vitro diagnostic and life science products. Dr. Vijayendran leads the development and oversees the manufacturing of Astute Medical’s NephroCheck and other innovative, biomarker-based diagnostic products.
Prior to joining Astute Medical, Dr. Vijayendran held positions at Biosite, Inc. and Alere, Inc., where he led the technical development of cardiovascular immunodiagnostic products from research and development through product commercialization. He also previously held a scientific position with Caliper Technologies, Corp., developing microfluidic products for the life sciences. Dr. Vijayendran holds a doctorate degree in chemical engineering from the University of Illinois and a bachelor’s degree in chemical engineering from Cornell University.
Joe Anderberg, Ph.D., has over 30 years’ experience in research and development. He has over 50 issued and pending U.S. patents in areas ranging from immunoassay methods and readers to novel biomarker content.
As an early team member of Astute Medical Inc., Dr. Anderberg built the foundations of Astute’s discovery engine.
Prior to joining Astute Medical in 2008, Dr. Anderberg was Sr. Director of Quantitative R&D at Biosite Inc., a leading diagnostics company acquired by Inverness Medical Innovations for $1.7 billion. During his 11 years at Biosite, Dr. Anderberg’s primary role was the development and commercialization of Biosite’s Triage® Meter Platform. He also was a key member of the Biomarker Discovery Team, and invented an innovative assay technology.
Prior experience includes the development of SQUID magnetometer based research instruments at Conductus Inc. and metrology tools for the X-ray Mask and Electron Beam Exposure group at AT&T Bell Laboratories.
He earned a doctorate in physics from the University of California, San Diego and a bachelor’s in physics from Harvey Mudd College.